Given the strong monotherapy activity of ceralasertib at 25 mg/kg b.i.d. in the MC38 model, to enable assessment of the benefit with anti-PD-L1 to be visualized ceralasertib was dosed at 6.25 mg/kg b.i.d. Eight weeks after transfer, the chimerism (>90%) was confirmed and MC38 tumor cells were injected s.c. Similar to the results in WT mice (Supplementary Fig. 2), in mice reconstituted with WT BM, treatment with anti-PD-L1 alone or with ceralasertib alone did not have potent antitumor activity. This evidence concerns the gene CD274 and neoplasm.